NCT02657785 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
| NCT ID | NCT02657785 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Navy General Hospital, Beijing |
| Condition | Primary Central Nervous System Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2010-09 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2010-09 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
Eligibility Criteria
Inclusion criteria: * Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL). Exclusion criteria: * Involved sites other than the brain, meninges, CSF, or the eyes. * Age less than 18 years or greater than 75 years. * Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/L, platelets \<100 ×10\^9/L, and hemoglobin level\< 8 g/dL). * Known cause of immunosuppression (ie, HIV type I infection). * Any previous malignancy. * Creatinine clearance below 60 mL/min. * Heart insufficiency (NYHA IIIB or IV). * Uncontrolled infection. * Noncompensated active pulmonary or liver disease. * Previously treated for PCNSL, except by corticosteroids.
Contact & Investigator
Liren Qian, M.D.
STUDY CHAIR
Navy General Hospital, Beijing
Frequently Asked Questions
Who can join the NCT02657785 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Primary Central Nervous System Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT02657785 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT02657785 currently recruiting?
Yes, NCT02657785 is actively recruiting participants. Contact the research team at qlr2007@126.com for enrollment information.
Where is the NCT02657785 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT02657785 clinical trial?
NCT02657785 is sponsored by Navy General Hospital, Beijing. The principal investigator is Liren Qian, M.D. at Navy General Hospital, Beijing. The trial plans to enroll 100 participants.